Estimating clinical and economic impacts and cost-effectiveness of introducing 20-valent pneumococcal conjugate vaccine in Taiwan’s pediatric National Immunization Program and impacts of a delayed implementation

Following 13-valent pneumococcal conjugate vaccine (PCV13) introduction in Taiwan, pneumococcal disease incidence declined; however, incidences driven by non-PCV13 serotypes highlight the need for broader serotype coverage. In response to recent approval of 20-valent PCV (PCV20) for Taiwanese childr...

Descrición completa

Detalles Bibliográficos

Principais autores:	Ya-Min Yang, Yi-Wei Wang, An Ta, Elizabeth Vinand, Megan Rutherford, Liping Huang
Formato:	Artigo
Idioma:	Inglês
Publicado:	Taylor & Francis Group 2026-12-01
Series:	Human Vaccines & Immunotherapeutics
Assuntos:	Pneumococcal disease Taiwan cost-effectiveness analysis 20-valent pneumococcal conjugate vaccine 15-valent pneumococcal conjugate vaccine 13-valent pneumococcal conjugate vaccine
Acceso en liña:	https://www.tandfonline.com/doi/10.1080/21645515.2026.2694843
Tags:	Engadir etiqueta Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!